Comparative Immunogenicity and Efficacy of Thermostable (Lyophilized) and Liquid Formulation of Anthrax Vaccine Candidate AV7909

The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the anthrax vaccine adsorbed (AVA) (Emergent BioSolutions Inc., Lansing, MI) bulk drug substance adjuvanted with the immunostimula...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Vaccine
Autors principals: Smiley, M. Autumn, Sanford, Daniel C., Triplett, Cheryl A., Callahan, Daniel, Frolov, Vladimir, Look, Jee, Ruiz, Christian, Reece, Joshua J., Miles, Aaron, Ruiz, Ericka, Ionin, Boris, Shearer, Jeffry D., Savransky, Vladimir
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6764848/
https://ncbi.nlm.nih.gov/pubmed/31530467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2019.09.015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars